Loading...
Loading...
XOMA Corporation
XOMA, a leader in the discovery and development of therapeutic
antibodies, announced today that gevokizumab, the company's IL-1 beta
modulating antibody, has been granted Orphan Drug Designation by the U.S.
Food & Drug Administration (FDA) for the treatment of non-infectious
intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior
uveitis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in